C Diff Treatment

Vancomycin taper and pulse regimens are commonly used to treat recurrent Clostridioides difficile infections, but the mechanism by which these regimens might reduce recurrences is unclear. Here, we used a mouse model to test the hypothesis that pulse dosing of vancomycin after a 10-day treatm …

C. diff infection can cause severe intestinal inflammation. A new approach blocks the inflammation triggered by C. diff’s toxin.

In early 2016, the University of Wisconsin (UW) Health, in Madison, had the unenviable distinction of being in the bottom sixth percentile of U.S. hospitals in its ...

Research and innovation around Clostridium difficile infection (CDI) has been a multidisciplinary endeavor since discovery of the organism in 1978. The field of gastroenterology has contributed to our understanding of CDI as a disease caused by disruptions in the gut microbiome and led to advances i …

Infectious diseases are a leading contributor to death in the United States, and racial differences in clinical outcomes have been increasingly reported. Clostridioides difficile infection (CDI) is a growing public health concern, as it causes nearly half a million infections per year and considerab …

Subjects given omadacycline had high fecal concentrations with a distinct microbiome profile compared to vancomycin. These pharmacokinetic and microbiome properties may help explain its low risk to cause Clostridioides difficile infection and warrant further research into its development as an antib …

Clostridioides difficile (C. diff) is curable, but recurrence and lingering symptoms are common. Here’s what to expect after recovering from C. diff.

This data may bring patients with the rare immunobullous disease closer to an eventual FDA-approved treatment.

[This corrects the article DOI: 10.1093/jacamr/dlad033.].

The results of this study demonstrate that vancomycin and metronidazole have comparable outcomes in regards to treatment response for non-fulminant CDI. The study also reveals the high and quick impact of international guidelines on local prescription patterns. Further studies are needed in Saudi Ar …

Background: More than 20% of the population in the United States suffers from a disability, yet the impact of disability on post-operative outcomes remains understudied. This analysis aims to characterize post-operative infectious complications in patients with disability. Patien …

Dublin, Nov. 22, 2023 (GLOBE NEWSWIRE) -- The "Ridinilazole Emerging Drug Insight and Market Forecast - 2032" report has been added to ResearchAndMarkets.com's offering.This report provides comprehensive insights about ridinilazole for clostridium difficile infection (CDI) in the seven major markets. Ridinilazole (previously known as SMT19969), being developed by Summit Therapeutics, is an investigational bisbenzimidazole oral antimicrobial that targets C. difficile whilst sparing the gut microb

Christian John Lillis, co-founder and executive director at Peggy Lillis Foundation, discusses the role of the pharmacist in education that advances C diff awareness in the medical community.

Background Clostridioides difficile infection (CDI) is a major cause of diarrhea in hospitalized adult patients. This study aims to evaluate the clinical characteristics, clinical cure, recur...

The results of this study demonstrate that fidaxomicin is highly effective against C. perfringens strains of canine and feline origin. Although fidaxomicin is currently considered a critically important antimicrobial that has not yet been licensed for veterinary use, we consider that the results rep …

Background Clostridioides difficile infection (CDI) is a major cause of diarrhea in hospitalized adult patients. This study aims to evaluate the clinical characteristics, clinical cure, recur...

Among 23 patients with multiply recurrent Clostridiodies difficile infection (mrCDI) who received bezlotoxumab at the end of antibiotic treatment a sustained clinical response of 91 % at 30 days and 78 % at 90 days was achieved. Bezlotoxumab administered at the end of antibiotic treatment was effect …

'The Effect of Antibiotic Therapy for Clostridioides difficile Infection on Mortality and Other Patient-Relevant Outcomes' - Author's reply

While being treated for a C diff infection, a patient with COPD is found to have an irregular pulse. What does his ECG show?

People with pneumonia who have experienced Clostridioides difficile (C. diff) infections may be able to reduce recurrences if they take doxycycline instead of the standard treatment. The study comes as the US Centers for Disease Control kicked off C. diff awareness month Wednesday.

Virtually everyone carries the bacteria Clostridioides difficile, or C. diff. But half a million Americans a year develop a serious C. diff infection due to a gut microbiome imbalance. It di...

The development of new biological agents and small molecules has revolutionized the treatment of Inflammatory Bowel Disease (IBD). However, many patients do not respond or gradually lose their response, necessitating the search for other therapeutic strategies (1). In this clinical case, we describe …

When implementing healthcare innovations, clinical implementation coordinators facilitated the implementation process through their roles and responsibilities and acted as strategic partners in improving the adoption and sustainability of a fluoroquinolone preauthorization protocol.

HBO may have beneficial effect on CDI by shortening the symptomatic period and preventing recurrence.

The patient advocacy organization has events in place and is ready to launch its annual C diff awareness campaign.

Clostridioides difficile is a predominant nosocomial pathogen within the healthcare setting able to produce biofilms. Sub-minimum inhibitory concentrations (sub-MICs) of antibiotics trigger mechanisms affecting bacterial virulence, including increased adhesion and biofilm formation. The aim o …

Lab experiments support treating inflammation rather than bacteria

New phase 1B data support further investigation into Adiso Therapeutic's prospective treatment.

C. diff infection can cause severe intestinal inflammation. A new approach blocks the inflammation triggered by C. diff’s toxin.

Feuerstadt reviews ACG 2023 data showing live microbiota therapy provides consistent protection against rCDI in one of the most vulnerable patient populations.